Immunodiagnostics: A breakthrough technology revolutionizing infectious and chronic disease diagnosis

8 December 2016
2019_biotech_test_vial_discovery_big

In an Expert View piece, industry analyst  Allied Market Research considers the potential and progress of a growing stream of applied clinical immunology.

The world faces tremendous disease burden through growth in epidemics such as HIV-AIDS and hepatitis. Recently, the Zika disease has been circumambulating the globe. Most of these diseases have similar symptoms but if undiagnosed can lead to devastating consequences.

These infectious and chronic diseases can be efficiently combated through a thorough diagnosis and different immunodiagnostic tests and analyses. Immunodiagnostics plays a vital role in understanding disease in the human body. The proteins expressed in the sera of a diseased person are different than those in a healthy person. These proteins therefore act as markers to determine the diseased state.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology